SecBot SecBot
424B5 ·Filed Jun 5, 2026

CELC

Celcuity Inc.
MIXED
Impact 6/10
Horizonweeks Processed5mo ago SEC0001493152-26-027395
Notable filing: 424B5
Actionable Insight ◆ Mixed

Convertible note offering removes restrictive secured debt and extends runway into 2028, supporting commercial launch. However, the massive debt load (~$701M) and potential dilution from conversion at ~$124.53/share cap upside. Monitor FDA PDUFA on July 17, approval could de-risk the conversion premium. Preferred shares would benefit from the de-levering to unsecured debt.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$88.28
T+0 close · Jun 5, 2026 · via day close
Latest settled
+0.88%
T+60 · $89.06
Vs SPY
−3.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 5 $88.28entry
  2. T+1 · 5mo ago −0.96%α −1.19% · $87.43
  3. T+5 · 5mo ago +0.31%α −0.26% · $88.55
  4. T+20 · 4mo ago +23.00%α +21.13% · $108.58
  5. T+60 · 3mo ago +0.88%α −3.12% · $89.06

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celcuity is issuing $500M of 0.250% convertible senior notes due 2032 (plus $75M over-allotment). Net proceeds of ~$484.3M will fully repay the $137.9M secured term loan facility and fund working capital, commercial launch, and pipeline expansion through 2028. The de-levering to zero secured debt is a significant credit-positive event, but the large debt raise (~$201M prior converts + $500M new, totaling ~$701M) adds substantial leverage and potential dilution if converted.

Key Facts

  • $500M aggregate principal of 0.250% convertible senior notes due 2032
  • $75M over-allotment option, total $575M if fully exercised
  • Initial conversion price ~$124.53/share, ~40% premium to $88.95 stock price on June 3
  • Net proceeds ~$484.3M (or ~$557M with over-allotment)
  • Proceeds to fully repay $137.9M secured term loan, eliminating all secured debt
  • Post-offering, total long-term debt rises from $339.1M to $701.3M
  • Maturity August 1, 2032; interest 0.250% paid semi-annually
  • Not redeemable before August 6, 2029; convertible upon stock price conditions or certain corporate events
  • Mandatory contingent conversion triggers if stock exceeds 130% of conversion price for 20 of 30 trading days
  • FDA PDUFA date for gedatolisib NDA in PIK3CA WT breast cancer is July 17, 2026
  • Positive Phase 3 VIKTORIA-1 MT data announced June 2, 2026, sNDA planned Q3 2026

Financial Impact

De-levering: $137.9M secured debt eliminated; new debt: $500M-$575M. Net cash infusion ~$484M after expenses. Total debt rises from $339M to $701M. Prepayment fee of ~$2.6M incurred.

debtdilutionliquidityinterest expense

Risk Factors

  • ~$701M total debt after offering significantly increases financial leverage
  • Potential dilution from conversion: ~4M shares per $500M at $124.53, plus ~4M from existing 2031 converts at $51.30
  • Unsecured notes rank equal with existing 2031 converts but effectively junior to any future secured debt
  • No public trading market expected for the notes; illiquidity premium
  • If stock does not appreciate above $124.53, convert notes remain out of the money, overhang without upside
  • PIK element on prior term loan was expensive (~7.75%+2.85%); replacement with 0.25% coupon is cheaper but riskier (convertible)

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001493152-26-027395
Exhibit: ex107.htm0001493152-26-027395
Document: 0001493152-26-027395-index-headers.html0001493152-26-027395
Document: 0001493152-26-027395-index.html0001493152-26-027395
Document: 0001493152-26-027395.txt0001493152-26-027395

Track record

26 reports on CELC

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
  3. Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
  7. Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
  8. Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
  9. Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
  10. Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026